Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...

(TVTX) on Monday reported a loss of $37.1 million in its first quarter.

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

For the quarter ended March 2026, Travere Therapeutics (TVTX) reported revenue of $127.2 million, up 55.6% over the same period last year. EPS came in at -$0.39, compared to -$0.47 in the year-ago ...

Travere Therapeutics Inc. (NASDAQ:TVTX) reported first quarter results that fell short of Wall Street expectations, with both earnings and revenue missing analyst ...

Travere Therapeutics TVTX posted a profit for the first quarter on Monday. The company reported quarterly earnings of 5 cents ...

First quarter performance driven by strong year-over-year royalty revenue growth of 56%Reaffirms Previously Raised 2026 Full-Year Financial ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the first quarter ended March 31, 2026, ...

Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from ...

LightPath Technologies, Inc. ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today ...